Form 4: MaxCyte EVP Thomas M. Ross Executes Option and Sells Shares Under 10b5-1 Plan

Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., exercised stock options and sold shares of common stock according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Thomas M. Ross, the EVP of Global Sales at MaxCyte, Inc., executed a transaction involving the company's stock on June 20, 2024.
• Ross exercised an employee stock option to acquire 33,333 shares of common stock at a price of $1.641 per share.
• Simultaneously, Ross sold 33,333 shares of common stock at a weighted average price of $4.094, with individual sales ranging from $4.00 to $4.185.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2024.
• Following these transactions, Ross directly owns 25,000 shares of common stock and 66,667 derivative securities (employee stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of insider trading. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information driving the decision.

Key Dates